Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:AMED
Previous Symbol
CUSIP02343610
Phone225-292-2031
Debt
Debt-to-Equity Ratio0.12
Current Ratio1.06
Quick Ratio1.06
Price-To-Earnings
Trailing P/E Ratio58.96
Forward P/E Ratio36.40
P/E Growth1.94
Sales & Book Value
Annual Sales$1.53 billion
Price / Sales2.71
Cash Flow$2.7635 per share
Price / Cash Flow47.15
Book Value$15.22 per share
Price / Book8.56
Profitability
EPS (Most Recent Fiscal Year)$2.21
Net Income$30.30 million
Net Margins5.39%
Return on Equity23.27%
Return on Assets14.26%
Miscellaneous
Employees17,900
Outstanding Shares31,890,000
Market Cap$4.16 billion
OptionableOptionable
Amedisys (NASDAQ:AMED) Frequently Asked Questions
What is Amedisys' stock symbol?
Amedisys trades on the NASDAQ under the ticker symbol "AMED."
How were Amedisys' earnings last quarter?
Amedisys Inc (NASDAQ:AMED) issued its quarterly earnings results on Monday, October, 29th. The health services provider reported $0.95 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.77 by $0.18. The health services provider earned $417.34 million during the quarter, compared to the consensus estimate of $411.05 million. Amedisys had a return on equity of 23.27% and a net margin of 5.39%. The business's quarterly revenue was up 11.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.56 EPS. View Amedisys' Earnings History.
When is Amedisys' next earnings date?
What guidance has Amedisys issued on next quarter's earnings?
Amedisys issued an update on its FY18 earnings guidance on Monday, October, 29th. The company provided EPS guidance of $3.54-3.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.40. The company issued revenue guidance of $1.65-1.67 billion, compared to the consensus revenue estimate of $1.65 billion.Amedisys also updated its FY 2018 guidance to $3.54-3.60 EPS.
What price target have analysts set for AMED?
12 brokerages have issued twelve-month target prices for Amedisys' shares. Their predictions range from $63.00 to $139.00. On average, they anticipate Amedisys' stock price to reach $109.3333 in the next year. This suggests that the stock has a possible downside of 16.1%. View Analyst Price Targets for Amedisys.
What is the consensus analysts' recommendation for Amedisys?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amedisys.
Has Amedisys been receiving favorable news coverage?
Media stories about AMED stock have been trending positive on Sunday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amedisys earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave headlines about the health services provider a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the stock's share price in the next few days.
Who are some of Amedisys' key competitors?
Who are Amedisys' key executives?
Amedisys' management team includes the folowing people:
- Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 57)
- Mr. Scott G. Ginn, Chief Financial Officer (Age 49)
- Mr. Christopher T. Gerard, Chief Operating Officer (Age 51)
- Mr. Michael P. North, Chief Information Officer (Age 53)
- Mr. Pete Hartley, CTO & Sr. VP of Bus. Operations Systems
Who are Amedisys' major shareholders?
Amedisys' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.65%), Vanguard Group Inc. (10.43%), Dimensional Fund Advisors LP (3.33%), JPMorgan Chase & Co. (2.93%), Acadian Asset Management LLC (1.91%) and Wells Fargo & Company MN (1.78%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Lawrence R Pernosky, Michael Paul North and Scott G Ginn. View Institutional Ownership Trends for Amedisys.
Which institutional investors are selling Amedisys stock?
AMED stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Wells Fargo & Company MN, BlackRock Inc., FMR LLC, Bank of New York Mellon Corp, Eaton Vance Management, Loomis Sayles & Co. L P and DNB Asset Management AS. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Michael Paul North and Scott G Ginn. View Insider Buying and Selling for Amedisys.
Which institutional investors are buying Amedisys stock?
AMED stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Vanguard Group Inc., Fuller & Thaler Asset Management Inc., Alliancebernstein L.P., Morgan Stanley, Deutsche Bank AG, Castleark Management LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Amedisys.
How do I buy shares of Amedisys?
Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amedisys' stock price today?
One share of AMED stock can currently be purchased for approximately $130.30.
How big of a company is Amedisys?
Amedisys has a market capitalization of $4.16 billion and generates $1.53 billion in revenue each year. The health services provider earns $30.30 million in net income (profit) each year or $2.21 on an earnings per share basis. Amedisys employs 17,900 workers across the globe.
What is Amedisys' official website?
How can I contact Amedisys?
Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]
MarketBeat Community Rating for Amedisys (NASDAQ AMED)
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
